Patents

Isis and Alnylam win U.S. patent for chemical modifications of oligonucleotide therapeutics

Published in Pharma Investments, Ventures and Law Weekly, December 31st, 2006

Isis Pharmaceuticals, Inc., (ISIS) and Alnylam Pharmaceuticals, Inc., (ALNY) announced that a key patent was issued by the United States Patent & Trademark Office covering certain chemical modifications of oligonucleotides used to introduce "drug-like" properties in antisense oligonucleotides, including small interfering RNAs (siRNAs), the molecules that mediate RNA interference (RNAi).

The U.S. patent (U.S. patent no. 7,138,517) is owned by Isis and is licensed exclusively to Alnylam for double-stranded RNAi therapeutic applications pursuant to the terms of their 2004 collaboration and license agreement.

"Our intellectual property estate continues...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly

Source: Pharma Investments, Ventures and Law Weekly (2006-12-31)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry